BioCentury
ARTICLE | Politics & Policy

ICER updates value assessment framework

June 23, 2017 9:06 PM UTC

The Institute for Clinical and Economic Review issued the final version of the framework and methods it will use from 2017-19 to guide its evidence reports, following a public consultation process with stakeholders.

ICER will now base prices in its cost-effectiveness analyses on estimates of prices net of rebates in the U.S. market, instead of wholesale acquisition costs (WACs). The organization said it would maintain the existing range of incremental cost-effectiveness ratios used to assess the value of treatments at $100,000-$150,000 per quality-adjusted life year (QALY), rather than dropping the lower bound to $50,000 per QALY as it had proposed. However, independent appraisal committees at ICER public meetings will now vote on a broader range of $50,000-$175,000 per QALY...